Pinpoint Genomics releases Pinpoint Dx Lung Assay
Pinpoint Genomics has made available its Pinpoint Dx Lung Assay to clinicians and patients through the company's laboratory in California, US.
The assay is a molecular diagnostic assay that differentiates between patients at high, intermediate or low risk of early death after surgery to remove a non-squamous, non-small cell lung cancer in patients with early stage disease.
The Pinpoint Dx Lung assay is run on surgical specimens that undergo routine handling by pathology laboratories, making it immediately available to virtually all patients, and is offered through Pinpoint's Clinical Laboratory Improvement Amendment-certified laboratory.
The company also announced the publication of key data relating to its Pinpoint Dx Lung Assay in the journal The Lancet.
The report in The Lancet describes the development of the assay based on specimens from 361 patients as well as the results of the two largest independent, blinded studies to evaluate the clinical validity of a multi-gene molecular diagnostic assay for early stage lung cancer.
Related Insight
Suppliers Directory
Malvern Instruments - Particle Size and Particle Shape Analysis, Zeta Potential, NIR-Chemical Imaging, Rheology and SEC
Malvern Instruments is a market leader in measuring performance controlling material properties.
Automation > Laboratory Instrumentation > Suppliers
VITLAB® - Competence in Labware
VITLAB® is a leading manufacturer of liquid handling equipment and plastic laboratory products and has distinguished itself as a specialist in the development and manufacture of high quality laboratory products made of a wide variety of plastics. Whether volume measuring, titration, dosing, pipetting, or saving and storing: The goal of our development is the creation of products which facilitate your daily lab tasks and deliver perfect results.
Automation > Laboratory Instrumentation > Suppliers
GoIndustry DoveBid - Industrial Asset Management, Auction and Valuation Services
GoIndustry DoveBid plc is the global market leader in the provision of asset management, auction and valuation services relating to industrial equipment.
Automation > Laboratory Instrumentation > Suppliers
AqVida Oncology - High Barrier to Entry Oncology Generics and Biosimilars
The main focus of AqVida Oncology lies with the development and manufacturing of innovative products, particularly high barrier to entry oncology generics and biosimilars.
Automation > Laboratory Instrumentation > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Laboratory Instrumentation Intelligence
Hydrogenation & Catalysis Tools
Published by HEL Group
Automation > Laboratory Instrumentation > White Papers
Reduced Solvent Consumption and Operational Costs with Existing LC Systems
Published by Shimadzu PBR
Automation > Laboratory Instrumentation > White Papers
Tips & Tricks - GPC/SEC: Copolymer Analysis in GPC/SEC 3 - Two-Dimensional Chromatography
Published by Polymer Standards Service
Automation > Laboratory Instrumentation > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.